Introduction {#sec1-1}
============

According to the World Health Organization, adverse drug reactions (ADRs) are considered as any noxious and unintended response to a medication that occurs at normal doses used for prophylaxis, diagnosis and/or treatment ([@ref1]). ADRs can be classified as A-type (dose dependent and predictable) and B-type reactions (dose-independent and unpredictable). A-type reactions: toxicity, side effects, interactions with other drugs. B-type reactions: hypersensitivity \[a. allergic reactions (immunonological mediated), e.g. IgE mediated or T-cells mediated; b. nonallergic reactions (non immunological mediated), e.g. pseudoallergy, intolerance, idiosyncrasy\] ([@ref2]-[@ref3])\]. Drug allergies are drug hypersensitivity reactions (DHRs) for which a definite immunological mechanism is demonstrated. When a drug allergic reaction is suspected, DHR is the preferred term. Mechanistically, DHRs can be defined as allergic ([Table 1](#T1){ref-type="table"}) ([@ref4]) and non allergic. Allergies to non-antibiotic drugs in child are mainly to non-steroidal anti-inflammatory drugs (NSAIDs), perioperative drugs, radio contrast media, chemotherapeutics drugs ([@ref5]).

###### 

Classification of drug allergies

  Type of immune response                          Physiopathology                             Main clinical symptoms                                 Chronology (after the drug)
  ------------------------------------------------ ------------------------------------------- ------------------------------------------------------ --------------------------------------------------------
  IgE mediated                                     Mast cell, basophil degranulation           Anaphylaxis, angioedema, urticaria, rhinitis, asthma   within 6 hours after the last intake
  IgG and complement                               IgG and complement-Dependent cytotoxicity   Cytopenia                                              5-15 days after the start
  IgM or IgG and complement or FcR                 Deposition of immune complexes              Vaculitis, Serum sickness                              7-21 days after the start 7-8 days after the start
  Th1 (IFN-γ)                                      Monocytes inflammation                      Dermatitis                                             within 21 days after the start
  Th2 (IL-4 and IL-5)                              Eosinophilic inflammation                   Maculopapular exanthema DRESS                          several days after the start 2-6 weeks after the start
  Cytotoxic T cells (perforin, granzyme B, FasL)   Keratinocyte death mediated by CD4 or CD8   SJS/TEN                                                4-28 days after the start
  T cells (IL-8/CXCL8) exanthematous pustulosis    Neutrophil inflammation                     Acute generalized                                      1 to several days

Non-steroidal anti-inflammatory drugs {#sec1-2}
=====================================

NSAIDs are commonly used in the pediatric population as antipyretics/analgesics and anti-inflammatory medications. Hypersensitivity (HS) reactions to NSAID in this age group have unique diagnostic and management issues ([Table 2](#T2){ref-type="table"}, [Table 3](#T3){ref-type="table"}) ([@ref6]).

###### 

Classification of non-steroidal anti-inflammatory hypersensitivity for the child aged (0-10 y) paediatric population

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Cross-reactivity                                    Type                                                                    Clinical of reaction                                                                                                      Chronology presentation                                                        Proposed mechanism   Cofactors (influence)
  --------------------------------------------------- ----------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------ -------------------- -----------------------
  Cross-intolerant reactions (Non-Allergic)           Non-allergic NSAID hypersensitivity (NERD, NECD, NIUAA)                 Urticaria, angioedema, dyspnea, rhinitis,                                                                                 Immediate, usually from minutes to several hours conjunctivitis, anaphylaxis   COX-1 inhibition\    Possible
                                                                                                                                                                                                                                                                                                                                       after exposure       

  Non-cross-Intolerant reactions (Allergic)           Selective NSAID- induced urticaria/angioedema or anaphylaxis (SNIUAA)   Urticaria, angioedema, anaphylaxis                                                                                        Immediate (\<1 h)                                                              IgE-mediated         Unknown

  Selective NSAID-induced delayed reactions (SNIDR)   Various symptoms and organs                                             Delayed onset T- cell- (usually more than 24 h involved after exposure) (e.g., fixed drug eruption, SJN/TEN, nephritis)   Unknown mediated                                                                                    
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

NSAIDs, non-steroidal anti-inflammatory drugs; COX-1, cyclooxygenase 1; SJS, Stevens-Johnson syndrome; TEN, toxic epidermal necrolysis

The term selective reactor (SR) ([Table 2](#T2){ref-type="table"}, [Table 3](#T3){ref-type="table"}) has been applied for cases in which the clinical manifestation is due to a single drug or single subclass of NSAIDs with good tolerability to other subclasses. In general, this term includes NSAID allergic hypersensitivity reactions.

###### 

Classification of non-steroidal anti-inflammatory hypersensitivity for the older paediatric population and adolescents (10-19 y)

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Cross-reactivity                             Type of reaction                                                         Clinical presentation                                                                        Chronology                                                     Mechanism                    Cofactors
  -------------------------------------------- ------------------------------------------------------------------------ -------------------------------------------------------------------------------------------- -------------------------------------------------------------- ---------------------------- -----------------------------------
  *Cross-intolerant reactions, non allergic*   NSAIDs-exacerbated respiratory disease                                   Bronchial obstruction, dyspnea, nasal congestion, (NERD)                                     minutes-hours after last intake                                COX1-inhibition              Asthma, rhinosinusitis rhinorrhea

                                               NSAIDs-exacerbated cutaneous disease                                     wheals and/or angioedema (NECD)                                                              minutes-hours after last intake                                COX1-inhibition              Chronic urticaria

                                               NSAIDs-induced urticaria/angioedema/anaphylaxis (NIUAA)                  wheals and/or angioedema and/or anaphylaxis                                                  minutes-hours after last intake                                COX1-inhibition (probably)   Unknown

  *Non-cross*\                                 Selective NSAID- induced urticaria/ angioedema or anaphylaxis (SNIUAA)   wheals and/or angioedema and/or anaphylaxis                                                  minutes after last intake                                      IgE mediated                 Unknown
  *Intolerant*\                                                                                                                                                                                                                                                                                                  
  *Reactions,*\                                                                                                                                                                                                                                                                                                  
  *Allergic*                                                                                                                                                                                                                                                                                                     

                                               Selective NSAID- induced delayed reactions (SNIDR)                       cutaneous and mucous reactions, complex reactions (e.g. SJS/TEN), organ-specific disorders   delayed onset (usually more than 24 hours after last intake)   T-cell mediated              Unknown
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

There are two well-defined phenotypes of selective HS reactions to NSAIDs:

a\. Selective NSAID-induced urticaria, angioedema, and/or anaphylaxis (SNIUAA): these are immediate reactions, probably mediated by a specific IgE antibody;

b\. Selective NSAID-induced delayed type HS reactions (SNIDR): these are reactions occurring within 24-48 hours after drug intake although the interval can be shorter. They are probably mediated by a specific T-cell response.

The term cross-reactor or according to the current classification, cross-intolerance (CI) reactions ([Table 2](#T2){ref-type="table"}, [Table 3](#T3){ref-type="table"}), is used in cases where the clinical manifestations are triggered by more than one subclass of NSAIDs, in which pharmacological mechanisms are the suspected pathophysiology. A combination of the inhibition of COX-1 in conjunction with an intrinsic regulatory defect in arachidonic-acid metabolism triggers a biochemical cascade involving the generation of leukotrienes and the release of mast-cell and eosinophil-derived mediators.

Ibuprofen is a safe alternative antipyretic, in children with a history of reactions to paracetamol as the molecular structure is quite dissimilar. All children with a suspected NSAIDs hypersensitivity reaction should be challenged and re-challenged periodically. COX2-specific medications, although generally not approved in children, have been prescribed and are useful as alternative medications. COX2-specific medications are the best option for all NSAID hypersensitive children. In children with NSAIDs hypersensitivity, a COX2-specific medication can be prescribed without a prior drug provocation test ([@ref6]). Algorithm for the management of children with non-steroidal anti-inflammatory drugs hypersensitivity reactions has been proposed ([@ref6]). In case of a confirmed hypersensitivity reaction to a single drug it is possible to use an alternative NSAID even if off label. If is present a cross-intolerance is possible a) use confirmed alternatives NSAID even if off label, b) use alternative drugs, c) use a desensitization in selective cases ([@ref6]).

Perioperative drugs {#sec1-3}
===================

Dewachter et al ([@ref7]) reported an overall incidence for perioperative anaphylaxis in the pediatric population of one in 7741 anesthetic procedures. Rates appear to be higher in selected populations, as in children with congenital malformations, submitted to several interventions ([@ref8]). In contrast to adults, neuromuscular blocking agents are less commonly incriminated in children, with an estimated incidence at one in 80 000 anesthetic procedures being the second leading cause after latex in this setting ([@ref9]). Anaphylaxis due to induction agents is rare. Brockow et al recommended drug concentration for skin testing aiming to achieve a specificity of at least 95%. It has been possible to recommend specific drug concentration for perioperative drugs, heparins, platinum salts and radio contrast media ([@ref10]) ([Table 4](#T4){ref-type="table"}). For the management of perioperative drug allergy it is necessary to carry out clinical history suggestive for DHR, in vivo and in vitro tests (if available), research of an alternative product, always through in vivo and in vitro tests, possible use of the responsible drug through a desensitization scheme.

###### 

Nonirritating test concentrations for main perioperative drugs and selected other drugs

  Drug Generic name   Undiluted Concentration (mg/ml)   Skin prick test   Intradermal test            
  ------------------- --------------------------------- ----------------- ------------------ -------- -------------
  Atracurium          10                                1/10              1                  1/1000   0.01
  Cis-atracurium      2                                 undiluted         2                  1/100    0.02
  Etomidate           2                                 undiluted         2                  1/10     0.2
  Fentanyl            0.05                              undiluted         0.05               1/10     0.005
  Propofol            10                                undiluted         10                 1/10     1
  Thiopental          25                                undiluted         25                 1/10     2.5
  Ketamine            10                                undiluted         10                 1/10     1
  Midazolam           5                                 undiluted         5                  1/10     0.5
  Sufentanil          0.005                             undiluted         0.005              1/10     0.0005
  Morphine            10                                1/10              1                  1/1000   0.01
  Mivacurium          2                                 1/10              0.2                1/1000   0.002
  Rocuronium          10                                undiluted         10                 1/200    0.05
  Vecuronium          4                                 undiluted         4                  1/10     0.4
  Suxamethonium       50                                1/5               10                 1/500    0
  Carboplatin                                                             10 mg/ml                    1 mg/ml
  Oxaliplatin                                                             1 mg/ml                     0.1 mg/ml
  Cisplatin                                                               1 mg/ml                     0.1 mg/ml
  Adalimumab                                                              50 mg/ml                    50 mg/ml
  Etanercept                                                              25 mg/ml                    5 mg/ml
  Infliximab                                                              10 mg/ml                    10 mg/ml
  Omalizumab                                                              1.25 mcg/ml                 1.25 mcg/ml
  Chlorhexedine                                                           5 mg/ml                     0.002 mg/ml

Radio contrast media {#sec1-4}
====================

The overall reported incidence of immediate reactions to intravenous nonionic iodinated radio contrast media in children is lower than in the adult population.

DHR with severe cardiovascular or respiratory involvement has been reported with an incidence of 0.07% for nonionic contrast media in children aged 1--19 years ([@ref11]). Gadolinium-containing contrast media were associated with DH reactions in 0.04% of the pediatric patients ([@ref12]-[@ref13]).

Chemotherapeutics drugs {#sec1-5}
=======================

Carboplatin and asparaginase are frequent causes of DH among treated children. In one review on children affected by low-grade glioma, 44 of 105 children (42%) developed hypersensitivity to carboplatin ([@ref14]). Seventeen (9.2%) of the 185 children, affected by different solid tumors and treated with etoposide--carboplatin, presented an allergic reaction to carboplatin: 2% at 6 courses, 11% at 12 courses, and 47% at more than 12 courses ([@ref15]).

Hypersensitivity reactions to asparaginase have been reported in up to 40% of the treated children ([@ref16]-[@ref17]).

It is useful, in case of suspected allergy to Radio contrast media and Chemotherapeutics drugs, follow the same indications given in case of suspected allergy to perioperative drugs.

Conclusions {#sec1-6}
===========

DHRs in children have a parent-reported prevalence of around 10%, with a much lower real prevalence, and a lower prevalence of confirmed DHRs as compared to adults ([@ref5]).

Beta lactams (BLs)are the main drugs implicated in DHRs among children and the most common cause of concern. Nonsteroidal anti-inflammatory drugs, non-BL antibiotics, perioperative drugs, anesthetics, radio contrast media, and cytotoxic drugs are also frequently suspected. The most common reactions are nonimmediate maculopapular exanthema and urticaria. Drugs are the third identified cause for anaphylaxis among children. Facial swelling associated with NSAID hypersensitivity appears to be quite specific for children. The diagnostic approach to DHR diagnosis is based on experience in adults, but its adequacy in children has to be further evaluated. For example, drug provocation test without previous skin tests can be considered in children with non-severe maculopapular and nonimmediate urticarial exanthemas ([@ref5]). Furthermore, there is higher evidence to recommend skin tests in children with suspected drug hypersensitivity to anticonvulsants, chlorhexidine (specific IgE determinations are available and recommended), heparins, neuromuscular blocking agents (specific IgE determinations are available and recommended), platinum salts, radiocontrast media, blue dyes, proton pump inhibitors ([@ref5]).
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